Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
India
/
Pharmaceuticals & Biotech
Create a narrative
Syngene International
NSEI:SYNGENE Community
1
Narratives
written by author
0
Comments
on narratives written by author
5
Fair Values set
on narratives written by author
Create a narrative
Syngene International
Popular
Undervalued
Overvalued
Syngene International
WA
Analyst Price Target
Consensus Narrative from 9 Analysts
New Pharma Partnerships And Operational Efficiencies Will Strengthen Future Prospects
Key Takeaways Expanding partnerships with pharma companies could drive revenue growth, as Syngene benefits from new and maturing collaborations. Strategic focus on digitization and supply chain diversification positions Syngene for improved margins and operational efficiency.
View narrative
₹878.13
FV
18.7% undervalued
intrinsic discount
16.28%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
23 days ago
author updated this narrative
Your Valuation for
SYNGENE
Syngene International
Your Fair Value
₹
Current Price
₹713.75
8.8% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
73b
2015
2018
2021
2024
2025
2027
2030
Revenue ₹72.6b
Earnings ₹10.3b
Advanced
Set as Fair Value